INN

Human medicines European public assessment report (EPAR): Qutenza, capsaicin, Date of authorisation: 15/05/2009, Revision: 19, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
Medical Subject Headings, Capsaicin, Marketing, European Commission, INN, HIV/AIDS, Infection, Diabetic neuropathy, ATC, Pain, Varicella zoster virus, International, European, Diabetes, Language, Shingles, Red, TRPV1, Trigeminal neuralgia, Neuropathic pain, HIV, Select, Committee, Patient, Risk management, Anatomy, Medicine, IIA, CHMP, Skin, Medical device

Human medicines European public assessment report (EPAR): Qutenza, capsaicin, Date of authorisation: 15/05/2009, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Qutenza, capsaicin, Date of authorisation: 15/05/2009, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Hycamtin, topotecan, Date of authorisation: 12/11/1996, Revision: 39, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
Marketing, Constipation, INN, Leukopenia, Woman, Carcinoma, Lung cancer, Fatigue, Nausea, DNA, Cancer, Neoplasm, Infection, SCLC, Mouth ulcer, Risk management, Anatomy, Paclitaxel, IIA, CHMP, Diarrhea, Fever, ATC, Capsule, European, Disease, Weakness, Mucositis, Anemia, Medical Subject Headings, Febrile neutropenia, European Commission, Cyclophosphamide, Vincristine, International, Neutropenia, Somatic symptom disorder, Aplastic anemia, Language, Cisplatin, Thrombocytopenia, Medication, Select, Patient, Medicine, Vomiting, Ovary, Survival, Ovarian cancer, Cervical cancer, Hair loss, Radiation, Doxorubicin, Committee, Medical device

Human medicines European public assessment report (EPAR): Hycamtin, topotecan, Date of authorisation: 12/11/1996, Revision: 39, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Hycamtin, topotecan, Date of authorisation: 12/11/1996, Revision: 39, Status: Authorised

Human medicines European public assessment report (EPAR): Clopidogrel Krka, clopidogrel, Date of authorisation: 23/09/2009, Revision: 19, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
Patient, Medical Subject Headings, Marketing, Acute coronary syndrome, Artery, European Commission, Agency, Moyamoya disease, INN, Risk, Platelet, ATC, Myocardial infarction, Bleeding, International, European, Blood, Language, Brain, Heart, Splenic infarction, Vascular disease, European Medicines Agency, Tablet, ADP, Select, Chest pain, Aspirin, Anatomy, Medicine, IIA, Atrial fibrillation, Medical device

Human medicines European public assessment report (EPAR): Clopidogrel Krka, clopidogrel, Date of authorisation: 23/09/2009, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Clopidogrel Krka, clopidogrel, Date of authorisation: 23/09/2009, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Leflunomide medac, leflunomide, Date of authorisation: 27/07/2010, Revision: 19, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
Medical Subject Headings, Marketing, Arava, European Commission, Arthritis, INN, Risk, ATC, Joint, Hepatotoxicity, DMARD, International, European, Disease, Language, Rheumatoid arthritis, Inflammation, Disease-modifying antirheumatic drug, Lymphocyte, Tablet, Select, Committee, Patient, Risk management, Anatomy, Medicine, Psoriatic arthritis, Methotrexate, IIA, CHMP, Skin, Medical device

Human medicines European public assessment report (EPAR): Leflunomide medac, leflunomide, Date of authorisation: 27/07/2010, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Leflunomide medac, leflunomide, Date of authorisation: 27/07/2010, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
Medical Subject Headings, Floater, Cataract, Marketing, Protein, BRVO, INN, Neovascularization, Complication, ATC, DME, Endophthalmitis, Retinal detachment, Blood, Bleeding, International, Ranibizumab, AMD, Injection, Disease, Diabetes, Language, CRVO, Eye, Pressure, Swelling, Inflammation, Intraocular pressure, RVO, European Medicines Agency, Infection, Cerebral edema, CNV, Growth, Select, Macular edema, Patient, Safety, Anatomy, Paratriathlon, Retina, IIA, Retinal haemorrhage, Three-body problem, Medical device

Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Emtricitabine/Tenofovir disoproxil Mylan, emtricitabine,tenofovir disoproxil, Date of authorisation: 16/12/2016, Revision: 15, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
Medical Subject Headings, Condom, Marketing, HIV-1, Tenofovir disoproxil, INN, Risk, Immune system, Health care, HIV/AIDS, Infection, Mylan, ATC, AIDS, International, Emtricitabine, Blood, Language, European Medicines Agency, Food, HIV, Tablet, Select, Subtypes of HIV, Patient, Cell, NRTI, Anatomy, Medicine, IIA, Pre-exposure prophylaxis, Generic drug

Human medicines European public assessment report (EPAR): Emtricitabine/Tenofovir disoproxil Mylan, emtricitabine,tenofovir disoproxil, Date of authorisation: 16/12/2016, Revision: 15, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Emtricitabine/Tenofovir disoproxil Mylan, emtricitabine,tenofovir disoproxil, Date of authorisation: 16/12/2016, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Relistor, methylnaltrexone bromide, Date of authorisation: 01/07/2008, Revision: 19, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
Patient, Medical Subject Headings, Diarrhea, Flatulence, Marketing, European Commission, Agency, INN, Constipation, Risk, Extrapyramidal system, Opioid, ATC, Bowel obstruction, International, Syringe, European, Spinal cord, Injection, Nausea, Language, Brain, Abdominal pain, Laxative, Naltrexone, Morphine, Disorder, Chronic pain, Select, Anatomy, Medicine, Palliative care, Dialysis, IIA, Skin, Medical device

Human medicines European public assessment report (EPAR): Relistor, methylnaltrexone bromide, Date of authorisation: 01/07/2008, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Relistor, methylnaltrexone bromide, Date of authorisation: 01/07/2008, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Trajenta, linagliptin, Date of authorisation: 23/08/2011, Revision: 21, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
Liver, Medical Subject Headings, Marketing, Kidney, European Commission, Diabetes, INN, Risk, Allergy, ATC, Hypoglycemia, Hormone, International, Diet, Pancreas, European, Insulin, Metformin, Disease, Blood, Language, Glycated hemoglobin, DPP-4, Glucose, Type, Tablet, Select, Committee, Patient, Safety, Pioglitazone, Anatomy, Medicine, IIA, CHMP, Exercise, Medical device

Human medicines European public assessment report (EPAR): Trajenta, linagliptin, Date of authorisation: 23/08/2011, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Trajenta, linagliptin, Date of authorisation: 23/08/2011, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
Medical Subject Headings, Diarrhea, Marketing, INN, Fever, Fatigue, ATC, Vincristine, HGG, BRAF, EMA, Xeroderma, Carboplatin, International, Bleeding, Cough, Headache, Nausea, Neutropenia, Language, Neoplasm, Cancer, Mutation, Neutrophil, Radiation, Water, European Medicines Agency, Tablet, MEK, Growth, Select, Patient, Cell, LGG, Safety, Anatomy, Vomiting, IIA, Rash, Medical device

Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Finlee, dabrafenib, Date of authorisation: 15/11/2023, Status: Authorised

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 29, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
Urine, Medical Subject Headings, Diarrhea, Marketing, INN, Risk, Immune system, Stomach, Interferon beta-1a, ATC, Pain, Multiple sclerosis, Capsule, International, RRMS, Spinal cord, Disease, PML, Ageing, Nausea, Language, Brain, Mouth, Eye, Inflammation, Flushing, European Medicines Agency, Food, Gene, Glatiramer acetate, Select, Central nervous system, Patient, Safety, Encephalitis, Anatomy, Sclerosis, Optic nerve, IIA, Skin, Medical device

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 29, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 29, Status: Authorised